{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:38Z","timestamp":1793406458612,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cmi.2025.11.009","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:36:15Z","timestamp":1763346975000},"page":"543-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Avoiding resistance development to newer drugs: open research lines"],"prefix":"10.1016","volume":"32","author":[{"given":"Matteo","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.11.009_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jgar.2024.03.018","article-title":"Risk factors and mortality of carbapenem-resistant Pseudomonas aeruginosa bloodstream infection in haematology department: a 10-year retrospective study","volume":"37","author":"Yuan","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.11.009_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ajic.2019.03.020","article-title":"Association between carbapenem-resistant Enterobacteriaceae and death: a systematic review and meta-analysis","volume":"47","author":"Soontaros","year":"2019","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2025.11.009_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cmi.2025.02.018","article-title":"Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: a 5-year cohort study in intensive care patients","volume":"31","author":"Karakonstantis","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.009_bib4","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/jac\/dkaf080","article-title":"Antipseudomonal cephalosporins versus piperacillin\/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?","volume":"80","author":"Bavaro","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.009_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.11.009_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2023.100723","article-title":"Global resistance of imipenem\/relebactam against gram-negative bacilli: systematic review and meta-analysis","volume":"100","author":"Abniki","year":"2024","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.cmi.2025.11.009_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107103","article-title":"Global trends in nonsusceptibility rates of Escherichia coli isolates to meropenem and ceftazidime\/avibactam: data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-21","volume":"63","author":"Wang","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: the new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.11.009_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14787210.2023.2169131","article-title":"Jumping into the future: overcoming pharmacokinetic\/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams","volume":"21","author":"Gatti","year":"2023","journal-title":"Expert Rev Anti-Infective Ther"},{"key":"10.1016\/j.cmi.2025.11.009_bib15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2025.11.009_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","article-title":"Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis","volume":"28","author":"Gatti","year":"2024","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2025.11.009_bib17","doi-asserted-by":"crossref","unstructured":"Gatti M, Cojutti PG, Rinaldi M, Ambretti S, Giannella M, Viale P, et al. Utility of a TDM-guided expert clinical pharmacological advice program for optimizing the use of novel beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in a tertiary university hospital: An interim analysis. Ther Drug Monitor. DOI:https:\/\/doi.org\/10.1097\/FTD.0000000000001334.","DOI":"10.1097\/FTD.0000000000001334"},{"key":"10.1016\/j.cmi.2025.11.009_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00969-23","article-title":"Could an optimized joint pharmacokinetic\/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?","volume":"67","author":"Gatti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.actbio.2024.12.002","article-title":"Aggregation-prone antimicrobial peptides target gram-negative bacterial nucleic acids and protein synthesis","volume":"192","author":"Chen","year":"2025","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.cmi.2025.11.009_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/phar.70019","article-title":"Pharmacokinetics of continuous infusion ceftolozane\/tazobactam in two patients with extensive total body surface area burns","volume":"45","author":"Olivet","year":"2025","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.cmi.2025.11.009_bib21","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/antibiotics12071214","article-title":"Real-life experience of continuously infused ceftolozane\/tazobactam in patients with bronchiectasis and multidrug-resistant Pseudomonas aeruginosa infection in the outpatient setting","volume":"12","author":"Venuti","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.cmi.2025.11.009_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s13318-022-00772-x","article-title":"Therapeutic drug monitoring and prolonged infusions of ceftolozane\/tazobactam for MDR\/XDR Pseudomonas aeruginosa infections: an observational study","volume":"47","author":"Navarrete-Rouco","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.cmi.2025.11.009_bib23","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jac\/dkaf098","volume":"80","author":"Gatti","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106158","article-title":"Use of continuous-infusion ceftolozane\/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature","volume":"56","author":"Sheffield","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/jcpt\/6674305","article-title":"Pharmacokinetics\/pharmacodynamics and therapeutic drug monitoring of ceftazidime\/avibactam in patients with gram-negative bacterial infections","volume":"2025","author":"Han","year":"2025","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cmi.2025.11.009_bib26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/jac\/dkae091","article-title":"Ceftazidime\/avibactam serum concentration in patients on ECMO","volume":"79","author":"Curtiaud","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/jac\/dkae035","article-title":"The pharmacokinetics\/pharmacodynamics of ceftazidime\/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study","volume":"79","author":"Xu","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1163","article-title":"A descriptive pharmacokinetic\/pharmacodynamic analysis of ceftazidime-avibactam in a case series of critically ill patients with augmented renal clearance","volume":"12","author":"Xu","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.cmi.2025.11.009_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dkac439","article-title":"Pharmacokinetics\/pharmacodynamics and therapeutic drug monitoring of ceftazidime\/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections","volume":"78","author":"Fresan","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib30","volume":"69","author":"Gatti","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib31","volume":"61","author":"Gatti","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106992","article-title":"A descriptive pharmacokinetic\/pharmacodynamic analysis of continuous infusion meropenem\/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia","volume":"62","author":"Gatti","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","article-title":"Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)","volume":"24","author":"Abdulla","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2025.11.009_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/cc9091","article-title":"Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2025.11.009_bib35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.11.009_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106884","article-title":"Impact of a newly established expert clinical pharmacological advice programme based on therapeutic drug monitoring results in tailoring antimicrobial therapy hospital-wide in a tertiary university hospital: findings after the first year of implementation","volume":"62","author":"Cojutti","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib38","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.11.009_bib39","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/ciac506","article-title":"Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis","volume":"75","author":"Pai Mangalore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/dkx419","article-title":"In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae","volume":"73","author":"Nath","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/mdr.2019.0463","article-title":"In vitro activity of ceftazidime-avibactam alone and in combination with amikacin against colistin-resistant gram-negative pathogens","volume":"27","author":"Chen","year":"2021","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.cmi.2025.11.009_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00692-21","article-title":"Generating genotype-specific aminoglycoside combinations with ceftazidime\/avibactam for KPC-producing Klebsiella pneumoniae","volume":"65","author":"Huang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00585-21","article-title":"Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant Pseudomonas aeruginosa and their potential role against ceftazidime-avibactam-resistant isolates","volume":"9","author":"Montero","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.11.009_bib45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jac\/dkae451","article-title":"A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime\/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria","volume":"80","author":"Assefa","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib46","doi-asserted-by":"crossref","first-page":"ofz416","DOI":"10.1093\/ofid\/ofz416","article-title":"Higher MICs (>2 mg\/L) predict 30-day mortality in patients with lower respiratory tract infections caused by multidrug- and extensively drug-resistant Pseudomonas aeruginosa treated with ceftolozane\/tazobactam","volume":"6","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib51","doi-asserted-by":"crossref","first-page":"ofac492","DOI":"10.1093\/ofid\/ofac492.704","article-title":"Ceftazidime-avibactam alone or as combination therapy? Multicenter retrospective cohort analysis of clinical outcomes in patients with carbapenem-resistant gram-negative infection","volume":"9","author":"Mishuk","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/1120009X.2019.1709363","article-title":"Ceftazidime-avibactam susceptible to resistant KPC-producing Enterobacterales bloodstream infections: an observational study","volume":"32","author":"Iannaccone","year":"2020","journal-title":"J Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106344","article-title":"Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli","volume":"57","author":"Scudeller","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae273","article-title":"Outcomes and predictors of mortality in patients with KPC-Kp infections treated with meropenem vaborbactam: an observational multicenter study","volume":"11","author":"Tumbarello","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107247","article-title":"Intravenous fosfomycin as adjunctive therapy for gram-negative bacteria bloodstream infections: a propensity score adjusted retrospective cohort study","volume":"64","author":"Belati","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol - compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad329","article-title":"Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic","volume":"10","author":"Giannella","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib62","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/microorganisms11040984","article-title":"Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic","volume":"11","author":"Mazzitelli","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2025.11.009_bib63","doi-asserted-by":"crossref","first-page":"dlac121","DOI":"10.1093\/jacamr\/dlac121","article-title":"Effect of ceftazidime\/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study","volume":"4","author":"Oliva","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.11.009_bib64","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol versus colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted, monocentric cohort study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.11.009_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107365","article-title":"Efficacy of fosfomycin-containing regimens in treating severe infections caused by KPC-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii in critically ill patients","volume":"64","author":"Oliva","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5946\/ce.2019.009","article-title":"Fecal microbiota transplantation: an update on clinical practice","volume":"52","author":"Kim","year":"2019","journal-title":"Clin Endosc"},{"key":"10.1016\/j.cmi.2025.11.009_bib67","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jinf.2022.04.028","article-title":"Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: a systematic review","volume":"84","author":"Macare\u00f1o-Castro","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2025.11.009_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo2750","article-title":"Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement","volume":"15","author":"Woodworth","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2025.11.009_bib69","article-title":"Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO): a feasibility randomised controlled trial","volume":"91","author":"Merrick","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2025.11.009_bib70","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/cid\/ciaa948","article-title":"Disease prevention not decolonization: a model for fecal microbiota transplantation in patients colonized with multidrug-resistant organisms","volume":"72","author":"Ghani","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib71","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cmi.2021.11.006","article-title":"How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection","volume":"28","author":"Ghani","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.009_bib72","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s10096-021-04296-1","article-title":"Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions","volume":"40","author":"Tompkins","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage therapy: a renewed approach to combat antibiotic-resistant bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmi.2025.11.009_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2041","article-title":"The dawn of phage therapy","volume":"29","author":"Rehman","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cmi.2025.11.009_bib75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199473","article-title":"Isolation and characterization of lytic bacteriophage vB_KpnP_23: a promising antimicrobial candidate against carbapenem-resistant Klebsiella pneumoniae","volume":"350","author":"Wang","year":"2024","journal-title":"Virus Res"},{"key":"10.1016\/j.cmi.2025.11.009_bib77","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1038\/s41598-020-62691-8","article-title":"Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates","volume":"10","author":"Horv\u00e1th","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2025.11.009_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/antibiotics10060672","article-title":"Advances in bacteriophage therapy against relevant multidrug-resistant pathogens","volume":"10","author":"Broncano-Lavado","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.cmi.2025.11.009_bib79","article-title":"Heterogeneous Klebsiella pneumoniae co-infections complicate personalized bacteriophage therapy","volume":"10","author":"Qin","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2025.11.009_bib80","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/cid\/ciaa705","article-title":"Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity","volume":"73","author":"Cano","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib81","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/cid\/ciz782","article-title":"Eradication of a multidrug-resistant, carbapenemase-producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom made, lytic bacteriophage preparation","volume":"70","author":"Corbellino","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib82","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/22221751.2020.1747950","article-title":"Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae","volume":"9","author":"Bao","year":"2020","journal-title":"Emerg Microbe Infect"},{"key":"10.1016\/j.cmi.2025.11.009_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13391","article-title":"Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy","volume":"23","author":"Rostkowska","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.009_bib84","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01281-19","article-title":"A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient","volume":"64","author":"Kuipers","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.11.009_bib85","doi-asserted-by":"crossref","unstructured":"Fu S-Y, Chen X-Z, Yi P-C, Gao J, Wang W-X, Gu S-L, et al. Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: Insights into dose and timing. Antimicrob Agents Chemother. n.d.;69:e01683-24. DOI:https:\/\/doi.org\/10.1128\/aac.01683-24.","DOI":"10.1128\/aac.01683-24"},{"key":"10.1016\/j.cmi.2025.11.009_bib86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro2315","article-title":"Bacteriophage resistance mechanisms","volume":"8","author":"Labrie","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2025.11.009_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107221","article-title":"Bacteriophage-resistant carbapenem-resistant Klebsiella pneumoniae shows reduced antibiotic resistance and virulence","volume":"64","author":"Chen","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.11.009_bib88","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s40121-021-00533-4","article-title":"Current stage in the development of Klebsiella pneumoniae vaccines","volume":"10","author":"Assoni","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.11.009_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1080059","article-title":"A new dawn for monoclonal antibodies against antimicrobial resistant bacteria","volume":"13","author":"Troisi","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2025.11.009_bib90","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.11.027","article-title":"Development of immunization trials against Klebsiella pneumoniae","volume":"30","author":"Ahmad","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.009_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70061","article-title":"Human vaccine candidates for infections caused by Klebsiella pneumoniae: a systematic review","volume":"7","author":"Motamed","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.cmi.2025.11.009_bib92","unstructured":"Clinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniae | K-VAX | Projekt | Fact Sheet | HORIZON. CORDIS Eun Comn n.d. https:\/\/cordis.europa.eu\/project\/id\/101189068."},{"key":"10.1016\/j.cmi.2025.11.009_bib93","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial","volume":"40","author":"Fran\u00e7ois","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2025.11.009_bib94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13054-022-04204-9","article-title":"Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial","volume":"26","author":"Chastre","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2025.11.009_bib95","first-page":"1","article-title":"Monoclonal antibodies protect against pandrug-resistant Klebsiella pneumoniae","author":"Roscioli","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2025.11.009_bib96","unstructured":"PrIMAVeRa Project. PrIMAVeRa n.d. https:\/\/www.primavera-amr.eu."},{"key":"10.1016\/j.cmi.2025.11.009_bib97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s44259-025-00087-2","article-title":"Emerging antimicrobial therapies for Gram-negative infections in human clinical use","volume":"3","author":"Hickson","year":"2025","journal-title":"Npj Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.11.009_bib98","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Discovery of antimicrobial peptides with notable antibacterial potency by an LLM-based foundation model","volume":"11","author":"Wang","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.cmi.2025.11.009_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad085","article-title":"Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study","volume":"5","author":"Rando","year":"2023","journal-title":"JAC Antimicrob Resist"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:56:29Z","timestamp":1773676589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1198743X25005609"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.009","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avoiding resistance development to newer drugs: open research lines","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}